Status:
COMPLETED
Enhancement of Calmness and Mood Following Acute Lemon Balm Supplementation During Cognitive Demand in Adults
Lead Sponsor:
University of Reading
Collaborating Sponsors:
Naturex
Conditions:
Stress
Mood Disturbance
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
This study aims to investigate the effect of a single dose (300mg) of encapsulated aqueous lemon balm extract on measures of calmness and mood during periods of cognitive demand over the course of the...
Detailed Description
Cognitive overload can be a common occurrence in an information saturated world (Eppler et al., 2008; Graf et al., 2021; Pass et al., 2004), and chronic cognitive overload is considered an initiating ...
Eligibility Criteria
Inclusion
- Healthy, between 18-40 years old
- Moderate Stress problems (PSS between 14 to 26)
- No alcohol or vigorous activity 24h before the task
- No coffee/caffeine intake 12h before the visits
- Non-smokers or Must not smoke during 7 days prior to the trial: Includes smoking tobacco, vaping nicotine, using nicotine replacement products, or occasional social smoking.
- Willingness to wash out for food supplementation during 2 weeks before the experiment
Exclusion
- Use medications that may affect the outcome
- Any long-term psychological or physiological health conditions
- Have any allergic reactions to ingredients in the capsules
- Have a BMI greater than or equal to 30
- Have any allergic reactions to ingredients in the capsules
- Consumed more than 400 mg of caffeine (\>5 expresso) per day in the past 2 weeks
- Have used any psychotropic medications, stimulants, cannabis, non-registered drug products, or illicit substances in the past 2 weeks, were at risk of drug or alcohol abuse
- Taking any dietary supplements which they are unwilling to stop for the duration of the study
- Have sleep disorders or are taking sleep aid medication
- Fail to demonstrate adequate minimal performance on lab, computer-based cognitive tasks
- Have a diagnosed neurological condition, or learning/behavioural or neurodevelopmental differences (e.g. dyslexia, autism, ADHD).
Key Trial Info
Start Date :
December 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT06183372
Start Date
December 2 2023
End Date
July 31 2024
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Reading
Reading, United Kingdom, RG2 9AH